Bernie Sanders could use his position in shaping the FDA funding bill to press for changes, according to STAT. The report notes that Sanders, a known critic of the pharmaceutical industry, may seek to include reforms as part of the funding process.
This development could affect regulatory requirements or pricing strategies for pharma and biotech firms. Senior executives should pay close attention to the bill’s progress, as any amendments could have direct effects on compliance, market access or costs.
